US 12350318
Combination therapy to treat brain cancer
granted A61KA61K2039/51A61K2039/54
Quick answer
US patent 12350318 (Combination therapy to treat brain cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/51, A61K2039/54, A61K2039/545, A61K2039/555